Compare Costco Wholesale Corporation (COST) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Sana Biotechnology Inc — how do they compare? Costco Wholesale Corporation trades at $946.46 (market cap $420.05B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: Costco Wholesale Corporation is far larger — about 502× Sana Biotechnology Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 133 Days and Sana Biotechnology Inc for 23 Days on average.
| COST | SANA | |
|---|---|---|
Market Cap | $420.05B | $836.71M |
Volume | 2,087,565 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $5.92 |
52-Week Low | $849.63 | $2.68 |
Typical Hold Time | 133 Days | 23 Days |
Enterprise Value | $407.33B | $749.96M |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $944.20, up 0.21% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong March 2026 sales growth of 11.3% year-over-year (Costco Wholesale Corporation, April 8, 2026) and has shown consistent revenue and net income growth, with fiscal 2025 revenue at $275.24B and net income at $8.10B. Analyst consensus is strongly bullish with a $1,100 price target, though valuation ratios like a P/E of 45.66 are elevated.
The outlook remains positive due to robust membership fee growth and expansion, but risks include high valuation sensitivity and competitive pressures. Upside is supported by strong institutional buying and earnings beats, though any market pullback could pressure the stock given its premium multiples.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
